Windtree Therapeutics Stock Performance
| WINT Stock | USD 0.02 0.00 0.00% |
The firm maintains a market beta of 4.92, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Windtree Therapeutics will likely underperform. At this point, Windtree Therapeutics has a negative expected return of -2.07%. Please make sure to check out Windtree Therapeutics' jensen alpha and rate of daily change , to decide if Windtree Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Windtree Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in February 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:50 | Dividend Date 2020-04-29 | Last Split Date 2025-02-21 |
1 | Windtree Therapeutics Inc. stock retracement recovery analysis - Trade Exit Summary Verified Entry Point Signals - newser.com | 10/31/2025 |
2 | Is Windtree Therapeutics Inc. stock a good choice for value investors - Weekly Investment Report Weekly Watchlist for Hot Stocks - newser.com | 11/04/2025 |
3 | Will Windtree Therapeutics Inc. price bounce be sustainable - Weekly Profit Report Fast Gaining Stock Reports - newser.com | 11/11/2025 |
4 | Windtree Therapeutics announces patents allowed in Canada, Mexico WINT | 11/14/2025 |
5 | Windtree Therapeutics sees 78.9M franchise milestone, royalty potential - Stock Titan | 11/17/2025 |
6 | Windtree Therapeutics Receives 7 Million Offer for Preclinical Oncology Platform - MSN | 01/06/2026 |
7 | Resistance Check Why Windtree Therapeutics Inc stock remains undervalued - Treasury Yields AI Forecast for Swing Trade Picks - moha.gov.vn | 01/13/2026 |
8 | Acquisition by Strobeck Mark of 3450 shares of Windtree Therapeutics at 1.21 subject to Rule 16b-3 | 01/23/2026 |
| Begin Period Cash Flow | 4.5 M | |
| Total Cashflows From Investing Activities | -12 K |
Windtree Therapeutics Relative Risk vs. Return Landscape
If you would invest 10.00 in Windtree Therapeutics on October 29, 2025 and sell it today you would lose (8.00) from holding Windtree Therapeutics or give up 80.0% of portfolio value over 90 days. Windtree Therapeutics is currently does not generate positive expected returns and assumes 10.1034% risk (volatility on return distribution) over the 90 days horizon. In different words, 90% of stocks are less volatile than Windtree, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Windtree Therapeutics Target Price Odds to finish over Current Price
The tendency of Windtree Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.02 | 90 days | 0.02 | about 88.98 |
Based on a normal probability distribution, the odds of Windtree Therapeutics to move above the current price in 90 days from now is about 88.98 (This Windtree Therapeutics probability density function shows the probability of Windtree Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 4.92 . This entails as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Windtree Therapeutics will likely underperform. Additionally Windtree Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Windtree Therapeutics Price Density |
| Price |
Predictive Modules for Windtree Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Windtree Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Windtree Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Windtree Therapeutics is not an exception. The market had few large corrections towards the Windtree Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Windtree Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Windtree Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -2.48 | |
β | Beta against Dow Jones | 4.92 | |
σ | Overall volatility | 0.03 | |
Ir | Information ratio | -0.21 |
Windtree Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Windtree Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Windtree Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Windtree Therapeutics generated a negative expected return over the last 90 days | |
| Windtree Therapeutics has high historical volatility and very poor performance | |
| Windtree Therapeutics has some characteristics of a very speculative penny stock | |
| Windtree Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (1.79 M) with loss before overhead, payroll, taxes, and interest of (17.79 M). | |
| Windtree Therapeutics currently holds about 11.38 M in cash with (15.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: Resistance Check Why Windtree Therapeutics Inc stock remains undervalued - Treasury Yields AI Forecast for Swing Trade Picks - moha.gov.vn |
Windtree Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Windtree Stock often depends not only on the future outlook of the current and potential Windtree Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Windtree Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 52.6 K | |
| Cash And Short Term Investments | 1.8 M |
Windtree Therapeutics Fundamentals Growth
Windtree Stock prices reflect investors' perceptions of the future prospects and financial health of Windtree Therapeutics, and Windtree Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Windtree Stock performance.
| Return On Equity | -4.13 | ||||
| Return On Asset | -0.35 | ||||
| Current Valuation | 13.45 M | ||||
| Shares Outstanding | 33.63 M | ||||
| Price To Earning | (0.05) X | ||||
| Price To Book | 0.61 X | ||||
| Price To Sales | 660.53 X | ||||
| Gross Profit | (17.79 M) | ||||
| EBITDA | (1.47 M) | ||||
| Net Income | (1.79 M) | ||||
| Cash And Equivalents | 11.38 M | ||||
| Cash Per Share | 0.37 X | ||||
| Total Debt | 1.82 M | ||||
| Debt To Equity | 0.95 % | ||||
| Current Ratio | 2.47 X | ||||
| Book Value Per Share | 0.39 X | ||||
| Cash Flow From Operations | (15.4 M) | ||||
| Earnings Per Share | 62.60 X | ||||
| Market Capitalization | 2.02 M | ||||
| Total Asset | 27.88 M | ||||
| Retained Earnings | (846.61 M) | ||||
| Working Capital | (3.14 M) | ||||
| Current Asset | 40.79 M | ||||
| Current Liabilities | 11.07 M | ||||
About Windtree Therapeutics Performance
Assessing Windtree Therapeutics' fundamental ratios provides investors with valuable insights into Windtree Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Windtree Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 3.32 | 3.15 | |
| Return On Tangible Assets | (1.68) | (1.77) | |
| Return On Capital Employed | (1.02) | (1.07) | |
| Return On Assets | (0.18) | (0.19) | |
| Return On Equity | (0.63) | (0.66) |
Things to note about Windtree Therapeutics performance evaluation
Checking the ongoing alerts about Windtree Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Windtree Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Windtree Therapeutics generated a negative expected return over the last 90 days | |
| Windtree Therapeutics has high historical volatility and very poor performance | |
| Windtree Therapeutics has some characteristics of a very speculative penny stock | |
| Windtree Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (1.79 M) with loss before overhead, payroll, taxes, and interest of (17.79 M). | |
| Windtree Therapeutics currently holds about 11.38 M in cash with (15.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.37, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: Resistance Check Why Windtree Therapeutics Inc stock remains undervalued - Treasury Yields AI Forecast for Swing Trade Picks - moha.gov.vn |
- Analyzing Windtree Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Windtree Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Windtree Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Windtree Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Windtree Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Windtree Therapeutics' stock. These opinions can provide insight into Windtree Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Windtree Stock Analysis
When running Windtree Therapeutics' price analysis, check to measure Windtree Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Windtree Therapeutics is operating at the current time. Most of Windtree Therapeutics' value examination focuses on studying past and present price action to predict the probability of Windtree Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Windtree Therapeutics' price. Additionally, you may evaluate how the addition of Windtree Therapeutics to your portfolios can decrease your overall portfolio volatility.